My ePortfolio Register   

Dose escalation of CPI-613 with bendamustine for relapsed T Cell NHL

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.12.16
Views: 845
Rating:

Dr Zanetta Lamar - Wake Forest Baptist Medical Center, Winston-Salem, USA

Dr Lamar speaks with ecancertv at ASH 2016 about phase I dose escalation of CPI-613, a metabolic inhibitor, in combination with bendamustine.

She summarises the incidence and outlook of refractory T cell non-Hodgkin lymphoma (NHL), and the escalation of a small patient subgroup from 2000mg/m2, limited by toxicity.

The overall response rate was 80%, and Dr Lamar describes these initial results as signs of an important crack in the armour of T cell lymphoma.

CPI-613 was discussed further by Dr Tim Pardee here.

ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence